Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Inc. (STOK) is a biotechnology company headquartered in Bedford, Massachusetts, USA. The company is focused on developing therapies for genetic diseases by modulating RNA expression.

Stoke's lead product candidate is STK-001, an investigational therapy for the treatment of Dravet syndrome, a rare and severe genetic epilepsy. STK-001 is designed to upregulate the expression of a healthy copy of the SCN1A gene, which is mutated in most cases of Dravet syndrome. STK-001 is currently being evaluated in a Phase 1/2a clinical trial, and Stoke is also planning to initiate a Phase 2b clinical trial in the first half of 2022. Stoke is also developing other product candidates for the treatment of various genetic diseases, including STK-002, an investigational therapy for the treatment of genetic diseases caused by haploinsufficiency of a specific gene.

In October 2021, Stoke announced positive interim data from its Phase 1/2a clinical trial of STK-001 in patients with Dravet syndrome. The data showed that STK-001 was generally well-tolerated and demonstrated encouraging signs of clinical activity, including a reduction in seizure frequency and an improvement in seizure severity. The company plans to continue the development of STK-001 and expects to initiate additional clinical trials in the coming months.

The company has incurred significant research and development expenses as it continues to advance its pipeline of product candidates.